D-Pharm Ltd. is an Israel-based drug-development company. The Company is focused on developing drugs for the treatment of central nervous system (CNS) conditions. Its area of interest is in developing medicine for degenerative and age-related disorders. The Company’s product portfolio includes three clinical Phase II drug-candidates: THR-18 for thrombolysis, to restore blood flow to the brain, heart or lungs, which completed clinical Phase I and Phase II study in acute stroke patients receiving tPA; DP-VPA for the treatment of epilepsy, migraine and manic depression, which has completed a Phase II study in patients with complex partial epilepsy, and DP-b99, which contains calcium, zinc and copper ions and is used for the protection of cells under stress in acute pancreatitis. The Company’s two technology platforms Membrane Activated Chelator and Regulated Activation of Prodrug use lipid moieties conjugated onto actives such as metal ion chelators or drugs for site specific activation.